Comment
Author: Admin | 2025-04-28
Of LDH (dose related), decreased carnitine concentrations, hyperglycinemia Postmarketing reports: Decreased carnitine concentrations, hyponatremia, hyperglycinemia, weight gain[Ref]MusculoskeletalCommon (1% to 10%): Arthralgia, arthrosis, leg cramps, myalgia, myasthenia, twitchingUncommon (0.1% to 1%): Decreased bone mineral density, osteopenia, osteoporosis and fractures on long term therapyRare (less than 0.1%): Rhabdomyolysis, systemic lupus erythematosus Frequency not reported: Bone painPostmarketing reports: Fractures, decreased bone mineral density, osteopenia, osteoporosis, weakness, bone pain[Ref]OcularVery common (10% or more): Amblyopia/blurred vision, diplopiaCommon (1% to 10%): Abnormal vision, conjunctivitis, diplopia, dry eyes, eye pain[Ref]OncologicRare (less than 0.1%): Myelodysplastic syndrome[Ref]OtherVery common (10% or more): AstheniaCommon (1% to 10%): Back pain, chills, deafness, ear disorder, ear pain, face edema, fever, malaise, otitis media, tinnitus, vertigoFrequency not reported: Hypothermia, weaknessPostmarketing reports: Hearing loss[Ref]References1. (2001) "Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical2. Cerner Multum, Inc. "UK Summary of Product Characteristics."Further informationDivalproex sodium side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.Medical Disclaimer
Add Comment